The lawsuit centers on claims that Aardvark Therapeutics provided materially false information in its registration statement for its February 2025 initial public offering. According to the complaint, the company failed to disclose that ARD-101 lacked the safety profile previously presented to the market, leading to an overstatement of the drug's clinical and regulatory prospects. When the reality of these findings surfaced, investors reportedly sustained financial losses.
Aardvark Therapeutics Faces Class Action Lawsuit Over IPO Disclosures
Investors who purchased Aardvark Therapeutics, Inc. securities between February 13, 2025, and May 14, 2026, are being sought for a class action lawsuit. The legal action, filed by Rosen Law Firm, alleges that the company issued misleading statements regarding the safety and commercial viability of its drug candidate, ARD-101.
Investors wishing to serve as lead plaintiff in this litigation must submit a motion to the court by October 13, 2026. While the lawsuit has been filed, no class has yet been certified. Individuals who purchased AARD stock during the specified period are not required to take immediate action to remain part of the class, nor does serving as lead plaintiff dictate the ability to participate in potential future settlements. Those interested in participating or seeking further information may contact Phillip Kim at Rosen Law Firm.
Comments (0)
No comments yet. Be the first!